We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly’s Phase II Stumble Puts Merck’s BACE Inhibitor in Lead
Lilly’s Phase II Stumble Puts Merck’s BACE Inhibitor in Lead
June 14, 2013
Eli Lilly’s decision to halt a mid-stage trial of its beta secretase (BACE) inhibitor drug to treat Alzheimer’s disease (AD) puts Merck’s own BACE inhibitor candidate in the lead, analysts say.